Press Releases

Press Releases

Date Title & Summary Additional Formats
01/10/20
Cidara Therapeutics Announces Proposed Rights Offering
Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced its intent to raise $30.0
12/03/19
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
ASH presentation will include new preclinical data on rezafungin for prevention of Pneumocystis SAN DIEGO , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will
11/18/19
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
Employee feedback places Cidara among top small companies in the area SAN DIEGO , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by
11/07/19
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate
11/05/19
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
SAN DIEGO , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14
10/03/19
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
SAN DIEGO , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which
09/16/19
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala , chief operating officer, and James Levine , chief financial officer of Cidara are
09/03/19
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan , which will be
08/21/19
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
SAN DIEGO --(BUSINESS WIRE)--Aug. 21, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak ® antiviral program have
08/08/19
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate activities